Table 3.

Effect of CXCL8 (KC) neutralization on terbutaline-sensitive alveolar fluid clearance at day 2 after RSV infection.

Treatment	Conc.	n*	% AFC30†	ΔTERBUT (%)‡
None	-	10	21.8 ± 2.3	-
Terbutaline	100μM	17	24 ± 2.3	10
Rat IgG2A	1μg/ml	7	23.8 ± 1.1	-
Rat IgG2A + Terbutaline	1μg/ml + 100μM	8	22.4 ± 1.8	-6
Anti-KC mAb§	1μg/ml	13	21 ± 1.3	-
Anti-KC mAb + Terbutaline	1μg/ml + 100μM	20	32 ± 0.94 a**	53
Anti-KC pAbb	1μg/ml	7	21.2 ± 2	-
Anti-KC pAb + Terbutaline	1μg/ml + 100μM	13	30.8 ± 1.9#	45
Anti-CXCR2 mAb§	1μg/ml	13	22.3 ± 2.1	-
Anti-CXCR2 mAb + Terbutaline	1μg/ml + 100μM	9	28.7 ± 0.8#	29
Anti-CXCR4 pAbb	1μg/ml	8	23. 7 ± 3.1	-
Anti-CXCR4 pAb + Terbutaline	1μg/ml + 100μM	10	24.5 ± 2.9	4

^*Number of mice in which AFC was evaluated

^†Mean % AFC ± SEM

^‡% change in mean AFC with terbutaline

^§Rat IgG_2A isotype

^a% AFC₃₀ in mock-infected mice is 34.8 ± 1.5 (n=11) (from ref. 4)

^bRabbit anti-rat polyclonal antibody

^#P<0.05,

^**P<0.005 versus untreated AFC at day 2